As a pan‐HER TKI, poziotinib has also been tested in other tumor types and yielded promising antitumor efficacy with manageable toxicity in HER2‐positive tumors, such as gastric cancer, breast cancer, and head and neck squamous cell carcinoma.168, 169. This evidence concerns the gene ERBB2 and neoplasm.